Janine Sengstack, Ph.D., is a cell biologist and entrepreneur advancing therapeutics for age-related diseases. She co-founded Junevity in 2023 to develop novel siRNA therapeutics for transcription factors, securing over $10 million in venture capital seed funding. During her doctorate work in cellular aging at UC San Francisco (UCSF), Sengstack created the foundation for the Junevity RESET discovery platform to find novel transcription factor targets to reverse aging in human cells. She was a finalist in the Nucleate Activator Program, receiving the Scientific Excellence Award. Sengstack was a Hillblom graduate fellow and received funding support from Chan Zuckerberg Biohub. She graduated from Cal Poly, San Luis Obispo with her Bachelor of Science in biology, summa cum laude.
At Junevity, Sengstack leads development of the RESET discovery platform from concept through siRNA candidate nomination for clinical development. Her work to date includes promising programs in metabolism and neurodegenerative diseases. She leads a team of scientists and participates in every part of growing the company, including fundraising and business development. Sengstack is a frequent speaker at conferences and podcasts about Junevity, the science of transcription factors and longevity, and inspiring the next generation of scientists and founders.